Top Suppliers:I want be here
Related CAS#:
139757-70-3 131791-83-8
926228-92-4 57335-98-5
73476-22-9 38258-99-0
66341-54-6 252681-09-7
57013-96-4 865604-21-3

76824-35-6

76824-35-6 structure
76824-35-6 structure
  • Name: Famotidine
  • Chemical Name: famotidine
  • CAS Number: 76824-35-6
  • Molecular Formula: C8H15N7O2S3
  • Molecular Weight: 337.445
  • Catalog: API Digestive system medication Acid and gastric mucosal protective drugs
  • Create Date: 2018-08-03 16:19:20
  • Modify Date: 2026-06-30 13:35:14
  • Famotidine is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.Target: Histamine H2 ReceptorFamotidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and it is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). Famotidine Group(2 mg/kg/day) were significantly lower than the equivalent parameters for the Control Group on both the third and seventh days post-surgery. famotidine exerts detrimental effects on the anastomotic bursting pressure and hydroxyproline content of perianastomotic tissues in the colon of rats [1]. famotidine increased the transgastric potential difference (PD) and promoted the recovery of decreased transgastric PD induced by acidified ethanol in rats. The preventive effect of famotidine on gastric lesions is attributable not only to suppression of acid secretion but to activation of the gastric mucosal defensive mechanisms [2].
Name famotidine
Synonyms FAMOTIDINE, IMP. C : 3-(2-DIAMINOMETHYLENAMINO-1,3-THIAZOL-4-YLMETHYL-SULPHANYL)-N-SULPHAMOYLPROPANAMIDE MM(CRM STANDD)
FAMOTIDINE, MM(CRM STANDD)
FAMOTIDINE, IMP. G (PHMEUROPA): AS MALEATE 3-[[[2-[(DIAMINOMETHYLENE)AMINO]THIAZOL-4-YL]METHYL]SULPHANYL]-N-CYANO-PROPANIMIDAMIDE MALEATE MM(CRM STANDD)
famoxal
Ulcetrax
3-[[2-(diaminomethylideneamino)-1,3-thiazol-4-yl]methylsulfanyl]-N'-sulfamoyl-propanimidamide
Ptrax
fanosin
FAMOTIDINE, IMP. E (PHMEUROPA): BIS[2-[[2-[(DIAMINOMETHYLENE)AMINO]-THIAZOL-4-YL]METHYL]]-DISULPHIDE MM(CRM STANDD)
FAMOTIDINE, DEADATION IMPURITY 1 BP STANDD
FAMOTIDINE, BP STANDD
Famodine
FAMOTIDINE, IMPURITY B3,5-BIS[2-[[[2-[(DIAMINOMETHYLENE)AMINO] THIAZOL-4-YL]METHYL]THIO]-ETHYL]-4H-1,2,4,6-THIATRIAZINE1,1-DIOXIDE STANDD
Pepcid
muclox
3-[(2-Diaminomethyleneaminothiazol-4-yl)methylthio]-N-sulfamoylpropionamidine
YM-11170
aminosulfonyl)
Famotidine,N′-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine
FAMOTIDINE, SULPHOXIDE MALEATE MM(CRM STANDD)
[1-Amino-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]propylidene]sulfamide
3-(2-GUANIDINOTHIAZOL-4-YLMETHYLTHIO)-N1-SULFAMOYLPROPIONAMIDE
Famotidine Histamine H2 rector antagonist
famodil
FAMOTIDINE, STANDD
N-(Aminosulfonyl)-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]methyl]thio]propanimidamide
FAMOTIDINE, DEADATION IMPURITY 2 BP STANDD
Pepcidine
fibonel
peptan
3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)thio)-n-(aminosulfonyl)p
famotidine Skype : honestcooperation
Famotidine I0E0630.997mg/mg(dr)
FAMOTIDINE, IMP. D : 3-(2-DIAMINOMETHYLENAMINO-1,3-THIAZOL-4-YLMETHYL-SULPHANYL)PROPANAMIDE MM(CRM STANDD)
FaMotidine (Pcid)
dispronil
famosan
Dispmmil
motiax
Propanimidamide, -(aminoiminomethyl)amino-4-thiazolylmethylthio-N-(aminosulfonyl)
3-[[[2-[(AMINOIMINOMETHYL)AMINO]-4-THIAZOLYL]METHYL]THIO]-N-(AMINOSULFONYL)PROPANIMIDAMIDE
pepdul
N'-[AMINOSULFONYL]-3-[(2-[DIAMINOMETHYLENEAMINO]-4-THIAZOLYL)METHYLTHIO]-PROPANAMIDINE
2-[4-[2-(amino-sulfamoylimino-methyl)ethylsulfanylmethyl]-1,3-thiazol-2-yl]guanidine
FAMOTIDINE, IMP. B AS DIMALONATE: 3,5-[2-[[[2-[(DIAMINOMETHYLENE)AMINO]THIAZOL-4-YL]METHYL]-SULPHANYL]ETHYL]-4H-1,2,4,6-THIATRIAZINE 1,1-DIOXIDE DIMALONATE MM(CRM STANDD)
FAMOTIDINE, IMP. F (PHMEUROPA): 3-(2-DIAMINOMETHYLEN-AMINO-1,3-THIAZOL-4-YLMETHYL-SULPHANYL)PROPIONIC ACID MM(CRM STANDD)
Famotidine &BP
Famotidine (Patented-No Supply)
FAMOTIDINE, IMP. A AS HYDROCHLORIDE: 3-[[[2-[DIAMINOMETHYLENE)AMINO]THIAZOL-4-YL]METHYL]-SULPHANYL]PROPANIMIDAMIDE HYDROCHLORIDE MM(CRM STANDD)
ganor
FAMOTIDINE, IMPURITY A3-[[[2-[(DIAMINOMETHYLENE)AMINO]THIAZOL-4-YL]METHYL]-THIO]PROPANAMIDE STANDD
FAMOTIDINE ASSAY STANDD BP(CRM STANDD)
Amfamox
3-(((2-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)-n(sup2)-sulfamoylp
MFCD00079297
[amino-3-[[[2-[(diaminomethylene)amino]-4-thiazolyl]-methyl]thio]propylidene]s
Ifada
N'-(Aminosulfonyl)-3-([2-(diaminomethyleneamino)-4-thiazolyl]methylthio)propanamidine
FAMOTIDINE, IMPURITY C BP STANDD
FAMOTIDINE
(Z)-3-(((2-((diaMinoMethylene)amino)thiazol-4-yl)Methyl)thio)-N'-sulfaMoylpropaniMidaMide
Gaster
amotidine
Dispromil
Description Famotidine is a competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.Target: Histamine H2 ReceptorFamotidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and it is commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD/GORD). Famotidine Group(2 mg/kg/day) were significantly lower than the equivalent parameters for the Control Group on both the third and seventh days post-surgery. famotidine exerts detrimental effects on the anastomotic bursting pressure and hydroxyproline content of perianastomotic tissues in the colon of rats [1]. famotidine increased the transgastric potential difference (PD) and promoted the recovery of decreased transgastric PD induced by acidified ethanol in rats. The preventive effect of famotidine on gastric lesions is attributable not only to suppression of acid secretion but to activation of the gastric mucosal defensive mechanisms [2].
Related Catalog
References

[1]. Inan, A., et al., Effects of the histamine H2 receptor antagonist famotidine on the healing of colonic anastomosis in rats. Clinics (Sao Paulo), 2009. 64(6): p. 567-70.

[2]. Miyata, K., et al., Studies on the mechanism for the gastric mucosal protection by famotidine in rats. Jpn J Pharmacol, 1991. 55(2): p. 211-22.
Density 1.8±0.1 g/cm3
Boiling Point 662.4±65.0 °C at 760 mmHg
Melting Point 163-164°C
Molecular Formula C8H15N7O2S3
Molecular Weight 337.445
Flash Point 354.4±34.3 °C
Exact Mass 337.044922
PSA 235.25000
LogP -0.40
Vapour Pressure 0.0±2.0 mmHg at 25°C
Index of Refraction 1.808
Storage condition Hygroscopic, -20°C Freezer, Under Inert Atmosphere
Water Solubility 1.1 mg/mL

CHEMICAL IDENTIFICATION

RTECS NUMBER :
UA2300000
CHEMICAL NAME :
Propanimidamide, 3-(((2-((aminoiminomethyl)amino)-4-thiazolyl)methyl)t hio)-N- (aminosulfonyl)-
CAS REGISTRY NUMBER :
76824-35-6
LAST UPDATED :
199709
DATA ITEMS CITED :
18
MOLECULAR FORMULA :
C8-H15-N7-O2-S3
MOLECULAR WEIGHT :
337.48

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
4 mg/kg/7D-I
TOXIC EFFECTS :
Liver - jaundice (or hyperbilirubinemia) hepatocellular
REFERENCE :
APHRER Annals of Pharmacotherpy. (Harvey Whitney Books Co., POB 42696, Cincinnati, OH 45242) V. 26- 1992- Volume(issue)/page/year: 28,40,1994
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
4049 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 19,544,1988
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
800 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DIGEBW Digestion. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 32(Suppl 1),7,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
800 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DIGEBW Digestion. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 32(Suppl 1),7,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
204 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 18,6125,1984
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
4686 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 16,590,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
778 mg/kg
TOXIC EFFECTS :
Behavioral - somnolence (general depressed activity) Behavioral - convulsions or effect on seizure threshold Lungs, Thorax, or Respiration - dyspnea
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 26,147,1983
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
800 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
DIGEBW Digestion. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 32(Suppl 1),7,1985
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
254 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 16,590,1985 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
18200 mg/kg/13W-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis) Skin and Appendages - dermatitis, other (after systemic exposure) Related to Chronic Data - death
REFERENCE :
DIGEBW Digestion. (S. Karger Pub., Inc., 79 Fifth Ave., New York, NY 10003) V.1- 1968- Volume(issue)/page/year: 32(Suppl 1),7,1985 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
2800 mg/kg
SEX/DURATION :
female 15-22 day(s) after conception lactating female 21 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 26,543,1983
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
22 gm/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Effects on Newborn - physical
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 26,489,1983
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
5500 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 26,489,1983
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1100 mg/kg
SEX/DURATION :
multigenerations
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 26,489,1983
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
248 gm/kg
SEX/DURATION :
male 12 week(s) pre-mating female 2 week(s) pre-mating - 4 day(s) post-birth
TOXIC EFFECTS :
Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive)
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 26,551,1983
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
2200 mg/kg
SEX/DURATION :
female 7-17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 26,831,1983
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
6500 mg/kg
SEX/DURATION :
female 6-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 26,565,1983
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
DOSE :
130 mg/kg
SEX/DURATION :
female 6-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
REFERENCE :
OYYAA2 Oyo Yakuri. Pharmacometrics. (Oyo Yakuri Kenkyukai, CPO Box 180, Sendai 980-91, Japan) V.1- 1967- Volume(issue)/page/year: 26,573,1983
Personal Protective Equipment Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
Hazard Codes T
Risk Phrases R20/21/22
Safety Phrases S22-S24/25
RIDADR NONH for all modes of transport
WGK Germany 2
RTECS UA2300000
HS Code 2935009090
Precursor  1

DownStream  2

HS Code 2935009090
Summary 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.

Chemsrc provides CAS#:76824-35-6 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 76824-35-6 | Chemsrc address: https://m.chemsrc.com/en/baike/947042.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2026 ChemSrc All Rights Reserved